Abstract: Introduction: The anti-CD38 antibody isatuximab (Isa) is approved in various countries with pomalidomide-dexamethasone for relapsed/refractory multiple myeloma (RRMM) patients (pts) with ?2 prior therapies including lenalidomide and a proteasome inhibitor, based on the ICARIA-MM study, and with carfilzomib-dexamethasone for RRMM pts with ?1 prior therapy, based on the IKEMA study. To enhance convenience of intravenous (IV) Isa administration, a shorter IV infusion over 30 minutes (30-min) was assessed in pts with NDMM not eligible/with no immediate intent for autologous stem cell transplantation (ASCT) still on maintenance therapy in a Phase 1b trial (NCT02513186). Results previously reported from this study showed efficacy of treatment with Isa in combination with bortezomib-cyclophosphamide-dexamethasone (VCd) or bortezomib-lenalidomide-dexamethasone (VRd), with manageable safety profiles. The rates of very good partial response or better and of minimal residual disease negativity (at 10 -5 sensitivity) were 80% and 53.3% with Isa-VCd, and 92.9% and 50.7%, respectively, with Isa-VRd [Ocio EM et al. HemaSphere 2023;7(2):e829; Ocio EM et al. Leukemia 2023;37(7):1521-1529]. Preliminary results with the new 30-min Isa administration method are presented here.
Methods: Pts still receiving maintenance treatment were to be switched to the 30-min infusion with Isa at 10 mg/kg diluted in a 250 mL infusion bag of 0.9% sodium chloride. The infusion rate of the first infusion was 250 mL/hr; in the absence of infusion reactions (IRs), subsequent infusions were to be administered at an infusion rate of 500 mL/hr. The objective was to evaluate safety in terms of incidence and severity of IRs during the first 2 full 30-min infusions. The initial, recommended premedication to be given at the time of the switch consisted of dexamethasone 20 mg orally (PO) (or equivalent [eq.]), acetaminophen (paracetamol) 650 to 1000 mg PO; ranitidine 50 mg IV (or eq.), diphenhydramine 25 to 50 mg IV (or eq.), and montelukast 10 mg PO (or eq.). Prior to switching, pts received weight-based Isa infusion in the VCd cohorts and initially in the VRd Part A cohort, followed by fixed-volume Isa infusion in both VRd Parts A and B (in Part B, at 200 mL/hr from 3 rd infusion, ~75 min with no IRs/interruptions).
Results: As of 19 May 2023, 29.4% of pts in Isa-VCd, 48.1% in Isa-VRd Part A, and 60.9% in Isa-VRd Part B were still on treatment. The median follow-up for all pts was 71.1, 55.1, and 38.1 months for the Isa-VCd, Isa-VRd Part A, and Isa-VRd Part B cohorts, with a median duration of exposure of 63.5, 54.1, and 40.8 months, respectively. A total of 45 pts received 142 infusions between Jan 2023 and May 2023: 45 first infusions with intermediate rate and 97 30-min infusions across cohorts, with a median of 3 cycles started by pts (range, 1-5) (44 pts received at least 2 infusions) and a median relative Isa dose intensity of 99.4% (range, 73.7-105.5%). Switching occurred at a median of 46 cycles (range, 38-88) for all treated pts. The median duration of Isa infusion in all treated pts was 32 min, 33 min, and 33 min at the 2 nd, 3 rd, and subsequent infusions, respectively ( Table). 30-min infusion of Isa was well tolerated, with no IRs and no infusion interruptions across cohorts.
Conclusions: These preliminary results show that 30-min infusion of Isa is a feasible, well-tolerated, and convenient administration method for pts with multiple myeloma on Isa treatment for several months. The 30-min Isa infusion is currently being assessed from day 1 of cycle 2 in the ongoing Phase 1-2 UMBRELLA trial of Isa with or without dexamethasone in combination with novel agents, conducted in pts with RRMM (NCT04643002).
Otras comunicaciones del congreso o articulos relacionados con autores/as de la Universidad de Cantabria
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development - Artículo de Revista
-
Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome - Artículo de Revista
-
Randomized phase 2 study of weekly carfilzomib 70 Mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple myeloma (RRMM) patients (GEM-KyCyDex) - Artículo de Revista
-
Hnrnpk overexpression drives nucleolar aberrancies causing ribosomopathies - Comunicación a Congreso
-
Genetic subtyping using whole exome sequencing across large B cell lymphoma entities in a series of 109 DLBCL and plasmablastic lymphoma cases - Comunicación a Congreso
-
Results from the cohort-expansion stage of a phase I trial of tinostamustine monotherapy in advanced Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL) and multiple myeloma (MM) (NCT02576496) - Comunicación a Congreso
-
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients - Artículo de Revista
-
The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis - Artículo de Revista
-
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma - Artículo de Revista
-
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile - Artículo de Revista
-
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma - Artículo de Revista
-
ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor - Artículo de Revista
-
Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies - Artículo de Revista
-
Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations - Artículo de Revista
-
Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia - Artículo de Revista
-
Natural history and cell of origin of TC F3- ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL - Artículo de Revista
-
Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs - Artículo de Revista
-
PLCG1 mutations in cutaneous T-cell lymphomas - Artículo de Revista
Congreso: The American Society of Hematology Annual Meeting Abstracts: ASH (65ª : 2023 : San Diego)
Editorial: American Society of Hematology
Año de publicación: 2023
Nº de páginas: 3
Tipo de publicación: Comunicación a Congreso
DOI: 10.1182/blood-2023-175020
ISSN: 0006-4971,1528-0020
Proyecto español: NCT02513186
Url de la publicación: https://doi.org/10.1182/blood-2023-175020